Pfizer has pulled the plug on its $70-million deal with Repligen to develop the latter’s spinal muscular atrophy programme.
The companies announced their collaboration early 2013, under which Pfizer gained a license to Repligen’s lead candidate RG3039, as well as backup compounds and enabling technologies, in return for $5m upfront and potential milestones of up to $65 million.
Since then, Repligen has picked up $2 million in milestone payments, including $1 million on January 8 this year, but last week a filing to the US Securities and Exchange Commission revealed that the license agreement will be terminated as of April 26.
Neither company has indicated the reason for the move.
